Seattle Genetics (SGEN) : On Friday, The money flowed into the Seattle Genetics (SGEN) stock with an uptick to downtick ratio was recorded at 1.19. Transactions worth $5.91 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $4.95 million. The total money flow into the stock was $0.96 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $0.89 million of block transactions on upticks. The total money flow in block trades was $0.89 million. In terms of price action, Seattle Genetics (SGEN) traded down $0.12 during the session at $44.78. Compared to the previous days closing, the stock was down only by -0.27%. For the week, the stock is -1.15%, over previous weeks closing.
The company Insiders own 33.3% of Seattle Genetics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -4.8% . Institutional Investors own 98.29% of Seattle Genetics shares. During last six month period, the net percent change held by insiders has seen a change of -5.1%.
In a related news,The officer (Chief Operating Officer) of Seattle Genetics Inc /Wa, Dobmeier Eric sold 12,589 shares at $48 on August 23, 2016. The Insider selling transaction had a total value worth of $604,272. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Seattle Genetics (NASDAQ:SGEN): stock was range-bound between the intraday low of $44.035 and the intraday high of $45.14 after having opened at $45.14 on Fridays session. The stock finally closed in the red at $45.14, a loss of -0.27%. The stock remained in the red for the whole trading day. The total traded volume was 526,199 shares. The stock failed to cross $45.14 in Fridays trading. The stocks closing price on Thursday was $44.9.
Seattle Genetics (SGEN) : During the past 4 weeks, traders have been relatively bearish on Seattle Genetics (SGEN), hence the stock is down -6.47% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.64% relative to the S&P 500. The 4-week change in the price of the stock is -6.59% and the stock has fallen -1.15% in the past 1 week.
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Companys marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, the Companys pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. In addition, it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics sugar-engineered antibody (SEA) technology.